For example, a recent study has indicated that enhancing the activity of CD5-positive dendritic cells can activate the response of effector CD8-positive T cells to tumors, thereby improving tumor immunogenicity and further enhancing the response rate to immunotherapy (He et al., 2023). Here, CD8A is linked to neoplasm.